Publication | Closed Access

Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier

Tumor BiologyMedicinePeptide LibraryPharmacologyImmunologyImmune Checkpoint InhibitorDrug CarrierTumor TargetingAnti-cancer AgentEndogenous Serum AlbuminImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentCancer ResearchTumor-selective Cytotoxic Peptide